Ge Long Hui·2025-07-24 11:33Group 1 - The core agreement between the company and Pfizer regarding the PD-1/VEGF bispecific antibody (SSGJ-707) has been established, with the license agreement effective from July 24, 2025 [1] - The company will receive a total of up to $150 million in non-refundable and non-offsettable option and exercise fees under the option agreement with Pfizer [1] - Pfizer has conditionally agreed to subscribe for 31.14 million shares at a price of HKD 25.2055 per share, totaling approximately HKD 785.0 million, which represents about 1.30% of the existing issued share capital [1] Group 2 - The net proceeds from the subscription will be approximately HKD 785.0 million, with around HKD 628.0 million (80% of the net proceeds) allocated for global research and development of clinical and preclinical projects, and improving production facilities [2] - Approximately HKD 157.0 million (20% of the net proceeds) will be used for other general corporate purposes [2] - The subscription is seen as an opportunity to raise additional funds and enhance the company's shareholder base with Pfizer as a strategic investor, supporting business growth and pipeline development [2]